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Abstract 
SerpinA12 (vaspin) is thought to be mainly expressed in adipose tissue and has multiple beneficial 
effects on metabolic, inflammatory and atherogenic processes related to obesity. Kallikrein 7 (KLK7) 
is the only known protease target of vaspin to date and is inhibited with a moderate inhibition rate. In 
the crystal structure, the cleavage site (P1-P1’) of the vaspin reactive center loop is fairly rigid compared 
to the flexible residues before P2, possibly supported by an ionic interaction of P1’ glutamate (Glu379) 
with an arginine residue (Arg302) of the ȕ-sheet C. A P1’ glutamate seems highly unusual and 
unfavorable for the protease KLK7. We characterized vaspin mutants to investigate the roles of these 
two residues in protease inhibition and recognition by vaspin. RCL mutations changing the P1’ residue 
or altering RCL conformation significantly increased inhibition parameters while removal of the positive 
charge within ȕ-sheet C impeded the serpin-protease interaction. Arg302 is a crucial contact to enable 
vaspin recognition by KLK7 and it supports moderate inhibition of the serpin despite the presence of 
the detrimental P1’ Glu379, which clearly represents a major limiting factor for vaspin inhibitory activity. 
We also show that the vaspin inhibition rate for KLK7 can be modestly increased by heparin and 
demonstrate that vaspin is a heparin-binding serpin. Noteworthy, we observed vaspin as a remarkably 
thermostable serpin and found residues Glu379 and Arg302 influencing heat-induced polymerization. 
These structural and functional results reveal the mechanistic basis of how reactive center loop sequence 
and exosite interaction in vaspin enable KLK7 recognition and regulate protease inhibition as well as 
stability of this adipose tissue derived serpin.  
 
Introduction
SerpinA12 (vaspin) is an inhibitory serpin first identified in white adipose tissue of the OLETF rat type-
2 diabetes model [1]. In humans, elevated vaspin mRNA and serum levels are associated with 
parameters of obesity and insulin resistance [2, 3]. Vaspin is a promising drug target with various 
beneficial effects on metabolic and atherogenic processes impaired or induced in overweight and obesity 
[4]. It has been suggested to function as a compensatory, anti-diabetic and anti-atherogenic protein in 
obesity related disorders such as insulin resistance and inflammation [5]. Under a high fat diet, vaspin 
transgenic mice gain less weight while exhibiting improved glucose tolerance and reduced adipose tissue 
inflammation [6]. Also central effects have been reported and central administration of vaspin reduced 
food intake in mice [7]. Kallikrein 7 (KLK7) is the only known protease target of vaspin by now and at 
least the beneficial effects on glucose tolerance in vivo are dependent on the protease inhibitor activity 
of vaspin [8]. KLK7 seems to be mainly expressed in skin where it is a key player in the desquamation 
of cornified skin layers [9]. Both proteins, KLK7 and vaspin, are reported to be involved in skin 
inflammation as in psoriasis, a chronic skin disease often related to obesity [10, 11]. KLK7 
overexpressing mice exhibit increased epidermal thickness, hyperkeratosis, and dermal inflammation 
[12, 13]. In humans, elevated KLK7 mRNA as well as KLK7 protein overexpression has been reported 
in various tumors such as ovarian, breast and cervical cancer [14-16]. Along these lines, a better 
understanding of vaspin function and regulation on a molecular level might lead to new strategies for 
pharmaceutical intervention or modulation of vaspin activity. 
Serpins inhibit protease targets using their reactive center loop (RCL) as substrate bait. After protease 
attack and acyl-enzyme complex formation, the protease-bound RCL integrates into the central serpin 
ȕ-sheet, thereby causing active-site distortion and preventing hydrolysis, final cleavage and release of 
the protease. The primary determinants of serpin specificity are the cleavage site and surrounding 
residues of the RCL. The crystal structure of human vaspin in its native conformation has been 
previously determined [8]. Vaspin exhibits interesting molecular aspects. As many other inhibitory 
serpins, vaspin exhibits a mostly flexible reactive center loop (RCL) unresolved in the crystal structure. 
The protease cleavage site appears more rigid compared to other serpin structures, possibly due to ionic 
interactions of P1’ Glu379 and Arg302 of the ȕ-sheet C in the crystal structure (Figure 1A). First of all, the 
highly unusual glutamate residue at the P1’ position of the protease cleavage site, which is unique 
amongst all human serpins, indicates functional relevance, particularly as the protease target KLK7 has 
a clear preference for basic residues at P1’ [17]. This might explain the moderate association rate and a 
comparatively high stoichiometry of inhibition observed for vaspin and KLK7 [8]. Also, Arg302, a well 
conserved residue in the serpin family, has been found to be of importance for protease recognition in 
other serpins [18, 19]. Here, we used a mutational approach to determine the influence of these two 
residues on KLK7 inhibition and on vaspin stability. Our results demonstrate the significant, yet 
opposing impact of both residues on vaspin activity. While P1’ Glu379 is an obvious down-regulator of 
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vaspin inhibitory activity, Arg302 represents a critical contact for KLK7 and enables a moderate 
inhibition rate for KLK7, potentially by offsetting the limitations of the unfavorable RCL sequence. 
Based on these results and properties from other serpins, we also investigated the possible activation of 
vaspin by heparin and found significant heparin-binding with a modest activation of vaspin. On a further 
note, investigating structural serpin parameters, we registered vaspin as a remarkably thermostable 
serpin and found both residues, Arg302 and Glu379, influencing serpin polymerization.  
 
Materials and methods 
Materials Human recombinant KLK7 and thermolysin were from R&D (Minneapolis, MN). 
Fluorogenic peptide substrate Mca-RPKPVE-Nva-WR-K(Dnp)-NH2 was from AnaSpec (Fremont, 
CA) and the substrate peptide Abz-KLYSSK-Q-EDDnp was a generous gift of Prof. Dr. Maria A. 
Juliano (Department of Biophysics, Escola Paulista de Medicina, Universidade Federal de São Paulo, 
Brazil). Human antithrombin III (AT) purified from human plasma was obtained from Thermo Fischer 
Scientific (Rockford, IL). Unfractionated heparin (ufh) was from Sigma-Aldrich, heparin 
oligosaccharide dp4 was from Iduron (Manchester, UK). All calculations were done using Prism 5.03 
(GraphPad Software). 
Generation of recombinant vaspin and KLK7 proteins Mutagenesis, recombinant expression and 
purification of vaspin and mutants was carried out as previously described with minor changes [8]. 
Disulfide bond containing mutants were dialyzed using an L-cysteine/-cystamine redox system 
(5 mM/1 mM). A polishing gel filtration step was performed after final dialysis using a HiLoad 16/60 
Superdex 200 column on an ÄKTA protein purification system (all from GE Healthcare, Freiburg, 
Germany). Purified proteins were analyzed by RP-HPLC, SDS-PAGE as well as MALDI-TOF mass 
spectrometry and were stored at 4 °C for up to one year without loss of activity. Recombinant expression 
and purification of KLK7 will be published in full detail elsewhere. Briefly, KLK7 was expressed as a 
fusion to the small ubiquitin-like modifier (SUMO) protein as inclusion bodies in E. coli. The fusion 
protein was refolded from guanidine by fast dilution in an arginine-glycerol buffer supplemented with 
a glutathione redox system. The SUMO protein was cleaved off with SUMO protease and purification 
of active KLK7 was performed using a HiTrap SP HP column followed by a final gel filtration step 
using a HiLoad 16/60 Superdex 200 column. Enzyme activity of recombinant KLK7 was comparable 
to commercially available KLK7 using the fluorogenic peptide Mca-RPKPVE-Nva-WR-K(Dnp)-NH2. 
Crystallization, X-ray data collection and structure determination For crystallization, gel filtration 
peak fractions were pooled and concentrated to 12 mg/ml. In a hanging-drop vapor diffusion setup at 
292 K, 1 ȝl protein and 1 ȝl crystallization buffer were mixed and equilibrated against 0.5 ml of 
crystallization buffer as reservoir solution. The analyzed crystals were transferred stepwise to a buffer 
containing 20% ethylene glycol in addition to the components in the crystallization buffer and frozen in 
liquid nitrogen. X-ray data collection was carried out at 100 K on beamline 14.1 of the Berlin 
Synchrotron (BESSY, Berlin, Germany) equipped with a PILATUS 6M detector (Dectris, Baden, 
Switzerland). The diffraction data were indexed, integrated and scaled with XDS [20] and aimless [21] 
of the CCP4 suite [22]. CoordinatesfromwildͲtypevaspin(pdb4IF8)weretakenasstartingmodelsfor
rigidbodyrefinementinREFMAC5[23,24].Models were further improved by iterative cycles of TLS 
refinement using REFMAC5 [23, 24] as well as BUSTER-TNT [25] and manual rebuilding with COOT 
[26]. The artificial disulfide bridge of chain A in the variant D305C/V383C was refined with an 
occupancy of 25 % in the reduced form. Reduction of the disulfide linkage could be unambiguously 
ascribed to radiation damage by using only the first 40 % of the data set (yielding a data completeness 
of 97.9 %) for refinement. With this data set the electron density showed no evidence for an open 
conformation of the disulfide bridge. In chain B, no alternative conformation was observed for the 
artificial disulfide bridge. We attribute this to the generally lower quality of the electron density of this 
chain, which is accompanied by significantly higher B-factors, most likely as a resulted of static disorder 
of this protein chain in the crystal. TLS groups (chain A: residues 36-70, 71-242, 243-308 and 309-414; 
chain B: residues 36-70, 71-176, 177-303, 304-413) were determined using the TLSMD web server [27, 
28]. Structures were validated by MOLPROBITY [29]. Final structure building and interpretation was 
aided by feature enhanced maps calculated with PHENIX [30, 31]. For crystallization of the E379S 
variant, a heparin tetrasaccharide was added to the crystallization buffer but no binding of the heparin 
was observed in the electron density maps. Crystals obtained in the absence of heparin showed identical 
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features (data not shown). Final coordinates and structure factors have been deposited in the Protein 
Data Bank (www.rcsb.org [32]) under accession codes 4Y3K (E379S) and 4Y40 (D305C/V383C) and 
relevant crystallographic data is specified in Table 1. Figures were prepared using PyMOL 
(www.pymol.org). 
Inhibition parameters. The stoichiometry of inhibition (SI) was determined as previously described 
[8]. A discontinuous assay was used to determine the rate of inhibition under pseudo-first order 
conditions for vaspin wild-type and mutants D305C/V383C, R302A, R302E, R302E/E379S with at least 
10-fold molar excess of inhibitor, as previously described [33]. Briefly, recombinant human KLK7 was 
activated according to the manufacturers’ protocol and the assay concentration of KLK7 was 19.2 nM 
in TBS buffer (50 mM Tris, 150 mM NaCl, pH 8.5). Inhibition reactions were stopped by addition of 
fluorogenic peptide substrate (30 μM) and residual KLK7 activity was measured on a FlexStation3 
Multi-Mode Microplate Reader (Molecular Devices, Sunnyvale, CA). The pseudo-first-order rate 
constant (kobs) was obtained from linear regression of semi-logarithmic plots of remaining KLK7 activity 
vs. time. Linear regression of kobs plotted against inhibitor concentration [I] resulted in the estimate of 
the second-order rate constant, ka.  
A continuous method was used to determine the rate of inhibition for vaspin mutant E379S with at least 
5-fold molar excess of inhibitor, as previously described [34]. The assay concentration of KLK7 was 
10 nM, the fluorogenic peptide was used at 25 μM. Here, kobs was determined by non-linear regression 
fitting of the progress curve to equation 1: 
ܲ ൌ ݒ଴݇௢௕௦ ሾͳ െ ݁
ି௞೚್ೞൈ௧ሿ 
P is the concentration of product at the time t and vo is the initial velocity for each [I]. Resulting kobs
values were plotted against [I] and the uncorrected second-order rate constant k’ was determined from 
the slope of linear fit. Finally, the second order rate constant, ka, was calculated by correcting k’ for 
substrate concentration [S], the KM of the protease and SI using equation 2: 
݇௔ ൌ ݇Ԣ ൈ ሺͳ ൅
ሾܵሿ
ܭெሻ ൈ ܵܫ 
The KM value for KLK7 was 15 ȝM. SI values and inhibition rates listed in Table 2 represent the average 
of at least three experiments from at least two protein batches.  
The pseudo-first-order rate constant (kobs) was furthermore determined in the presence of various 
concentrations of ufh (ufh:vaspin ratios of 1,56-,  12,5- and 100-fold) using the discontinuous method 
with 10-fold molar excess of inhibitor to maintain pseudo-first-order conditions. In these assays, the 
substrate peptide Abz-KLYSSK-Q-EDDnp [17]was used at a concentration of 7 μM. kobs values 
indicating for reaction speed were normalized to the reaction without ufh to estimate the relative heparin 
induced increase in activity. 
Complex formation analysis by SDS-PAGE To investigate complex formation, recombinant KLK7 
and vaspin, or mutants, were incubated at a ratio of 3:1 (protease:serpin; KLK7 concentration was 3.5 
μM) in TBS buffer (50 mM Tris, 150 mM NaCl, pH 8.5). At given time points samples containing 
0.5 μg of serpin were taken and the reaction was stopped by immediate addition of reducing SDS sample 
buffer and 5 min of heating at 95 °C. Protein separation by SDS-PAGE was performed using 4-12% 
Bis-Tris Plus precast gels and NuPAGE MES/SDS running buffer (all from Life Technologies, 
Carlsbad, CA). Gels were stained with Coomassie Blue, digitization and densitometric analysis were 
performed using GeneTools analysis software (Syngene). Estimation of SI values were calculated as the 
sum of band intensities for complexed and cleaved vaspin divided by the band intensity of complexed 
vaspin [35]. To analyze the effect of heparin on the vaspin-KLK7 reaction, complex formation assays 
were performed as described above with various concentrations of ufh (molar ratios of heparin to vaspin 
from 0.1 – 100) and the reactions were stopped after 1 min of incubation. Complex band intensities were 
then normalized to the reaction without heparin. 
Heparin affinity chromatography 200 μg of recombinant protein was used for heparin affinity 
chromatography with 1ml HiTrap Heparin HP columns on the ÄKTA protein purification system (both 
from GE Healthcare, Freiburg, Germany). Elution was performed by a sodium chloride gradient from 
150 mM to 2 M (flow rate: 1 ml/min) and monitored at 220 nm. 
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Thermal stability Circular dichroism (CD) spectra were recorded using 1 mm quartz cuvettes (Hellma, 
Jena, Germany) on a J-715 spectropolarimeter (Jasco, Tokyo, Japan) equipped with a Peltier-type 
temperature control system at 20 °C. Spectra were acquired as an average of three scans (2 nm 
bandwidth, 4 s response, 50 nm/min scan rate) and base-lines were corrected by subtraction of the buffer 
spectrum. The protein concentration was 1.5 μM in 10 mM phosphate buffer, pH 7.8.  Thermal unfolding 
was performed at a heating rate of 50 °C/h and monitored at 208 nm (data pitch 0.1 °C, sensitivity 
100 mdeg, 4 s response, band width 2 nm). Measured ellipticity ș was converted to mean residue molar 
ellipticity [ș] in deg·cm2·dmol-1 as previously described [36].  
Temperature induced polymerization 5 μM of antithrombin (AT), vaspin or mutants were heated for 
120 min at 60 °C or 70 °C in TBS buffer. During heating, samples were taken at indicated time points 
and non-reducing SDS-sample buffer was added. Vaspin-KLK7 complex formation after heating was 
analyzed as described above, with 2 min cooling on ice before incubation with KLK7 for 15 min. 
Polymerization and complex formation were analyzed by SDS-PAGE.  
Peptide synthesis and RP-HPLC based analysis of KLK7 cleavage Peptide synthesis, purification 
and analytics were performed as previously described [10]. For cleavage analysis, 250 μg vaspin(365-
388) was incubated with 2 μg KLK7 (327 nM) in a 250 μl reaction volume for 120 min at 37 °C. After 
incubation, proteolytic activity was terminated by boiling and the peptide mixtures were analyzed by 
RP-HPLC (Phenomenex Jupiter Proteo C18 column, 4.6 mm×250 mm, 90 Å pore size).  
Results 
Altering vaspin RCL constraints via two designed variants 
Vaspin and its mutants crystallize in space group C2 with two monomers in the asymmetric unit 
(Table 1). Although no systematic differences are observed between the two molecules, in monomer B 
the lack of crystal contacts results in a rigid body disorder of the whole subunit such that the regions 
close to the interaction interface with monomer A have low B-factors and well defined density and the 
complete subdomain comprising sheet 3 and the RCL exhibit high B-factors and ill-defined density 
(Supplementary Figure 1A, B). As a result, the density of the RCL and nearby regions is less well-
defined and fewer residues of the RCL could be modeled, including residues involved in the interactions 
described below. Since this is a result of a rigid body disorder of the whole subunit, these interactions 
are likely to be present but they are not evident by the electron density maps which are affected by the 
rigid body disorder. Therefore, the following observations, figures and calculations are based on 
chain A.  
In the crystal structure, the P1’ Glu379 forms a weak salt bridge with the side chain of Arg302 within 
strand 2 of ȕ–sheet C (s2C) and water-mediated hydrogen bonds with the main chain CO of Arg301. Also 
P2’ Thr380 interacts with the Arg302 side chain via a water-mediated hydrogen bond (Figure 1A). 
Collectively, these interactions could limit the overall flexibility of the C-terminal part of the RCL with 
the cleavage site. Noteworthy, RCL orientations in serpin crystal structures display great variability and 
do not necessarily represent the conformation of the free serpin in solution.  
We aimed to alter the cleavage site by mutating the P1’ glutamate to serine, a very common P1’ residue 
in the serpin family (E379S mutant) [37]. Also, a recent study investigated the primed subsite (S1’-S3’) 
preferences of KLK7 and demonstrated a clear P1’ preference for hydrophilic residues, especially 
arginine and serine [17]. To specifically dissect the effect of RCL flexibility or conformation from P1’ 
specificity of KLK7, we furthermore designed a variant, where we introduced a disulfide linkage at the 
C-terminal side of the cleavage site via the D305C/V383C double mutant. This disulfide bridge was 
intended to induce an altered RCL conformation while the native RCL sequence with respect to protease 
substrate specificity is preserved.  
Overall, the crystal structures of both mutants show no conformational differences to wild-type vaspin 
further away from the mutation sites, as demonstrated by r.m.s. deviations of 0.38 Å (E379S) and 0.33 Å 
(D305C/V383C) calculated for the CĮ atoms of chain A. The RCL hinge region of residues P15 to 
P13/P12 (residues 364-366/367) is well-defined and extends away from the central ȕ–sheet A. In 
contrast, the electron density for RCL residues P12/P11-P2 (G367/A368-P377) and the N-terminal RCL part 
is weak or absent indicating high flexibility in both structures, similar to the situation in wild-type vaspin 
(Supplementary Figure 1C). The only exception concerns RCL residues P1-P2’ (Met378 – Thr380). As 
mentioned above, in wild-type vaspin these residues are rather well defined (Figure 1A), but there is 
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weak ambiguous electron density in the E379S mutant structure indicating also a very flexible C-
terminal RCL (Figure 1B). In the D305C/V383C mutant, formation of the engineered disulfide bond 
was verified by the electron density maps (Figure 1C) and resulted in a band with a distinct shift on a 
non-reducing SDS gel, confirming full formation of the disulfide bond (Supplementary Figure 2). 
Comparable to the E379S mutant, the P1 and P1’ residues (Met378 and Glu379) also exhibit only weak 
electron density and thus are much more flexible compared to the wild-type vaspin structure (Figure 
1C). Hence, the successful introduction of the artificial disulfide linkage was sufficient to alter RCL 
conformation and both mutant structures exhibit less constrained RCLs. 
Change of RCL sequence and conformation results in accelerated and more efficient KLK7 
inhibition
Both, the introduction of the disulfide bond and P1’ exchange, resulted in significant improvement in 
serpin activity (Table 2). As expected, exchange of the P1’ residue in the E379S variant resulted in a 
dramatic rate acceleration of ~35-fold, requiring a change to a continuous assay, while all other mutants 
were characterized in a discontinuous assay (Table 2, Figure 2A). Also the D305C/V383C mutant 
exhibits a significant ~4.5-fold increase in KLK7 inhibition rate (Table 2, Figure 2B). This mutant 
features the native RCL sequence and thus the effect is independent of substrate specificity of KLK7. 
The SI measured for both vaspin mutants was ~2 (Table 2, Figure 2C). 
These results are also reflected in accelerated complex formation observed in SDS-PAGE analysis for 
both mutants (Figure 3A). The native RCL sequence seems to prevent a fast protease attack. After 60 min 
almost all serpin molecules are either cleaved or complexed for both mutants, whereas ~25% of wild-
type vaspin remains unaffected after 120 min (Figure 3A). In conclusion, mutation of the P1’ residue 
Glu379 to the more preferred serine demonstrates the explicit rate-reducing effect of the native P1’ 
residue in this system. Yet, an alteration of the RCL conformation could also moderately improve serpin 
activity despite the detrimental P1’ Glu379.  
 
Elimination of the positive charge at position 302 reveals a crucial contact for KLK7 recognition 
Since conformational alterations as induced by the disulfide-mutant increased vaspin inhibition rates, 
we investigated the existence of further determinants of activity and specificity in addition to the P1’ 
residue. We analyzed the importance of Arg302 in KLK7 inhibition by vaspin. This positively charged 
residue is well conserved throughout the serpin family and the orientation of the side chain is in good 
superposition in many serpin structures (Supplementary Figure 3). Furthermore, this arginine has been 
found to be a critical contact point in the Michaelis complex of heparin cofactor 2 (serpinD1) as well as 
thrombin [18], and is part of a basic exosite for the inhibition of tissue kallikrein by kallistatin (serpinA4) 
[19].  
For vaspin, the mutation of arginine to alanine (R302A) resulted in dramatic loss of inhibitory activity 
(~40-fold) compared to wild-type (Table 2, Figure 2B). This is also evident in the very slow complex 
formation (Figure 3B). Introduction of a negatively charged glutamate (R302E) resulted in almost 
complete prevention of the serpin-protease interaction and no measurable inhibitory activity (Table 2, 
Figure 2B, 3B). After 16 h of incubation only faint bands of complexed and cleaved serpin were detected 
with ~90% serpin remaining active. These results are also in line with the finding, that a synthetic peptide 
comprising the vaspin RCL sequence, vaspin(365-388), is not cleaved by KLK7 (Figure 3C). 
Densitometric estimation of the SI for the R302A and R302E mutants indicated an SI comparable to the 
wild-type vaspin (Table 2). Mutation of the Arg302 in the disulfide bond mutant (R302A/D305C/V383C, 
R302E/D305C/V383C) resulted in a similar loss of activity and serpin-protease interaction as observed 
in wild-type vaspin (Table 2, Figure 3D). As expected, loss of Arg302 in the E379S mutant did not 
completely prevent inhibition of KLK7, as the RCL sequence is adjusted to KLK7 subsite preference, 
but still slowed down the reaction by >90% (Table 2, Figure 3D). In conclusion, Arg302 comprises a 
crucial residue for initial KLK7-vaspin Michaelis complex formation with subsequent cleavage site 
attack promoting the inhibition reaction and bypassing the repressing effect of P1’ Glu379.  
Heparin activates vaspin and accelerates KLK7 inhibition 
We further investigated whether heparin, a common activator of serpin activity, is able to bind and 
activate vaspin. Indeed, vaspin as well as KLK7 bound to heparin-sepharose and eluted at ~580 mM and 
~420 mM NaCl in heparin-affinity chromatography experiments (Figure 4A). When evaluating the 
effect of heparin on vaspin activity, we found a concentration dependent increase of vaspin activity both, 
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by analyzing vaspin-KLK7 complex formation on SDS-PAGE gels (Figure 4B, C) and by measuring 
the inhibition rate for wt vaspin (Figure 4D). At the optimal ratio of heparin to vaspin (12.5-fold ufh in 
our experiments), we observed a modest ~5-fold increase in vaspin activity towards KLK7. The bell-
shaped dose-response curve for heparin activation may indicate activation via the bridging mechanism 
for vaspin and KLK7 by heparin.
Thermo-stability and vaspin polymerization 
Far-UV CD data reflected the structural similarity and demonstrated structural integrity for all mutants 
tested (Figure 5A). Thermal denaturation revealed a remarkable thermo-stability with temperature 
midpoints (Tm) of 70 °C and a well-defined isochromatic point suggests a two-state unfolding pathway 
progressing from the native to unfolded state (Figure 5B, C). Thermal unfolding seems irreversible and 
heat-induced aggregation and precipitation was observed. Vaspin was found considerably resistant to 
heat-induced inactivation by polymerization. Prolonged incubation of up to 120 min at 60 °C did not 
noticeably alter serpin activity analyzed via complex formation with KLK7 (Figure 5D). Also, polymers 
were almost undetectable in non-reducing, non-heated SDS-samples, whereas for AT, serving as a 
control, polymerization was apparent after 15 min at 60 °C (Figure 5E). As expected from the Tm values, 
increasing the temperature to 70 °C resulted in distinct vaspin polymer formation (Figure 5F). 
Polymerization was markedly enhanced in Arg302 deficient mutants and also observed for the disulfide 
mutant D305C/V383C. Polymerization for the E379S containing mutants was minor and alike the wild-
type. In conclusion, vaspin represents a highly thermo-stable serpin and Arg302 seems to hinder polymer 
formation in wild-type variants featuring the native Glu379.  
 
Discussion  
We have previously identified KLK7 as the first target protease of human vaspin inhibited with a 
moderate inhibition rate [8]. The RCL P1’ Glu379 residue, unique amongst all human serpins, indicates 
functional relevance. By changing the RCL sequence or conformation, the first by mutation of Glu379, 
the latter by an engineered disulfide bond, we observed increasing RCL flexibility in the crystal 
structures. Alongside, the mutants featured increased inhibition rates, with a far more pronounced 
increase in activity for the E379S mutant. This can be attributed to a much more preferred P1’ serine 
residue over glutamate for KLK7. The primed subsite (S1’-S2’) of KLK7 clearly prefers amino acids 
serine and arginine at the substrates P1’ and P2’ position and in a soluble peptide library P1’ glutamate 
featuring peptide substrates were all found resistant to hydrolysis [17]. In accordance with these data, 
no cleavage of a synthetic peptide comprising the RCL sequence of vaspin by KLK7 was observed. Yet, 
the significant effect on activity of the disulfide-bond demonstrates a moderate contribution of RCL 
conformation or flexibility, as this mutant exhibits the native RCL sequence. Together, these results 
clearly reveal, that the P1’ glutamate is detrimental to vaspins inhibitory activity and it may function as 
a regulatory element in reducing the inhibition rate.  
Related to this, almost a complete loss of inhibition and interaction was observed when mutating the 
positively charged Arg302 within s2C for all variants featuring the P1’ glutamate. The finding, that also 
the KLK7-adjusted RCL-mutant E379S loses ~90% of activity when lacking Arg302, further 
demonstrates the importance of this residue for KLK7 recognition. Together with the specificity studies 
on KLK7, these results highlight the necessity of Arg302 for KLK7 inhibition by vaspin to offset the 
effect of the impedimental P1’ glutamate and explain the moderate inhibitory activity of native vaspin 
observed for KLK7. In conclusion, Arg302 seems to represent a crucial contact for the serpin-protease 
interaction and its presence or access to it regulates whether or not the target protease KLK7 is inhibited 
at all. Thus, vaspin is an example of how serpins generate specificity via exosite interactions with their 
target proteases but at the cost of maximal inhibitory activity.  
In kallistatin, Arg308, the equivalent to vaspins Arg302, is part of an exosite with tissue kallikrein that 
comprises a cluster of positively charged residues (K307A/R308A and K312A/K313A all in s2C). 
Mutations of these positively charged residues in kallistatin resulted in 5 to 20-fold lower activity [19]. 
In kallistatin, this exosite is supposed to enable specific inhibition of kallikreins despite the kallistatin 
P1 Phe residue being inappropriate for kallikreins. The exosite mutations in kallistatin were performed 
as double mutations and there is no data on the effect of individual mutations of single charged residues. 
While with Arg302 in vaspin, a single mutation almost completely prevents KLK7 recognition and 
subsequent inhibition, it is likely, that more residues contribute to KLK7 recognition and binding, e.g. 
the neighboring Arg301, but also that other exosites are still to be identified.  
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In addition to exosites promoting binary complex formation of serpin and protease, there are also 
exosites involved in ternary complex formation with additional cofactors [38]. In light of the detrimental 
P1’ Glu379, we investigated if activity of vaspin could also be increased by cofactors, such as the 
glucosaminoglycan heparin. First, we found strong heparin binding for both vaspin and KLK7. Binding 
and activation of KLK7 by heparin has been previously reported, with KLK7 eluting at 0.3-0.4 mM 
NaCl from heparin-sepharose [17]. This is in line with our findings for the recombinant KLK7 used in 
our assays. Importantly, we also observed a modest, but distinct and concentration dependent heparin-
induced increase in KLK7 inhibition by vaspin (~5-fold). It is important to note, that the heparin induced 
vaspin activation was quantified accounting and normalizing for any heparin induced increase in KLK7 
activity, as KLK7 is also moderately activated by heparin (~2-fold at ~100-fold excess of GAG, [17]). 
The major contribution of GAG-activation of serpins comes via the template mechanism, i.e. bridging 
serpin and protease and directing a preferential orientation of protease and serpin RCL [38]. Also here, 
the bell-shaped dependence on heparin concentration suggests a bridging effect of heparin for vaspin 
activation, as very high GAG concentrations counteract the activating effect. Thus, vaspin is a heparin-
binding, though very modestly heparin-activated serpin. Interestingly, while there are similarities in this 
exosite residue for the two serpins vaspin and kallistatin, heparin binding has opposing effects for their 
activity. For kallistatin, heparin binding occurs at the exosite comprising Arg308 and in consequence 
counteracts protease inhibition [39]. As heparin is able to activate vaspin, the binding site has to be 
located somewhere else, or at least Arg302 is not likely to contribute to GAG binding and we are currently 
working on the identification of the GAG binding site in vaspin. 
Investigating the structural integrity of the generated mutants, we found vaspin to be remarkably 
thermostable, with a Tm of 70 °C compared to AT (Tm of 57 °C) or antitrypsin (Tm of 58 °C) [40, 41]. 
Thermopin, a thermostable serpin from the bacterium Thermofibia fusca has a Tm of 65 °C, enabling 
functionality at the preferred growth temperature of 55 °C [42]. The Tm was identical for all mutants 
tested. These data reveal no major thermodynamic importance of the potential interaction of Glu379 and 
Arg302 observed in the crystal structure and thus, further determinants are likely to contribute to the 
thermal stability of vaspin. Surprised by these findings, we were also interested in heat-induced 
polymerization for vaspin and variants. There are two pathways of serpin inactivation independent from 
protease attack, which are the latent transition and serpin polymerization. The transition into the latent 
conformation occurs via incorporation of the RCL into ȕ-sheet A, as for example observed for PAI-1 or 
AT [43-45]. Based on crystal structure data, the hinge region of vaspin is not partially incorporated into 
the central A-sheet as e.g. in native AT and we also have not observed considerable loss of activity for 
vaspin stored at 4 °C for months. Thus, vaspin seems not prone to undergo the latent transition. 
Alternatively, serpins are able to polymerize and the mechanism thought to most likely represent the in
vivo polymerization mechanism features a swap of major C-terminal domains involving strands s1C, 
s4B and s5B but RCL incorporation into the own central ȕ-sheet A, as for the latent transition [46]. In 
vivo, serpin polymerization is observed for mutations affecting folding, formation and stability of the 
native state, e.g. for the Z variant (E342K) of antitrypsin [47]. A recent study concluded that these 
mutations likely first of all affect the stability of the metastable native state and ultimately facilitate or 
hinder the irreversible polymerization step [41]. Serpin polymerization is heat-inducible and elevated 
temperatures inactivate most inhibitory serpins due to polymerization [48]. For vaspin, the residues 
Arg302 and Glu379 seem to affect heat-induced polymerization. Mutants featuring the native Glu379 
without Arg302 (R302A and R302E) polymerized more readily than the wild-type. In contrast, E379S 
containing mutants as well as mutation of Arg302 did not influence polymerization and were comparable 
to wild-type vaspin. Together, Glu379 seems to facilitate polymer formation, whereas Arg302 counteract 
and appears to stabilize vaspin as a monomer in the native state. On a side note, we were initially 
surprised to observe polymerization of the D305C/V383C mutant, as this disulfide bond should prevent 
extended RCL movement likely required for a domain-swap mechanism of polymerization. But recently, 
Irving et al. have also observed polymerization for a similarly disulfide-stabilized antitrypsin variant 
(S283C/P361C) [41].  
In conclusion, our data revealed Glu379 and Arg302 as important regulatory elements for serpin 
functionality, such as protease specificity, activity and stability and explain the observed moderate 
activity for the target protease KLK7. Thereby, RCL P1’ residue Glu379 is the down regulating element, 
whereas the exosite at Arg302 enables inhibition of KLK7 despite the obviously inappropriate P1’ 
residue. The reason underlying this deliberate limitation of vaspin activity by Glu379 has to be further 
investigated. It very likely enhances specificity for KLK7, because inhibition of other proteases 
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preferring similar P1 residues could be even more negatively affected by the presence of this P1' residue. 
Vaspin serum concentrations are very low and positively correlated with increasing fat mass, obesity 
and insulin resistance [4]. An important function of vaspin is its positive effect on insulin action, as 
application or overexpression in mice improves glucose tolerance [1, 6]. We have demonstrated that this 
effect is dependent on vaspins inhibitory activity [8]. Also, vaspin expression follows a circadian rhythm 
and peak levels of vaspin precede post prandial insulin secretion peaks [49] and an acute insulin dose in 
humans rapidly decreases vaspin serum levels [50]. In addition to avoid potentially adverse influence 
on non-target protease-mediated processes, a high specificity and prevention of vaspin consumption due 
to interaction with non-target proteases thus may be of great importance, given the low serum 
concentrations. Furthermore, heparin was identified as a first activating cofactor of vaspin. A detailed 
and better understanding of vaspin action and its regulation, the identification of further proteases 
targeted by vaspin and identification of the substrates of these proteases, should increase the 
understanding of the diverse beneficial effects of vaspin and lead to new pharmacologic targets and 
potentially new treatment strategies for obesity related metabolic and inflammatory diseases.  
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Figure Legends 
Figure 1. Crystal structure of human vaspin and mutants vaspin E379S and D305C/V383C. (A) 
Structure of human vaspin (pdb 4IF8) with ȕ-strands and loops shown in cyan and Į-helices in red. The 
dotted black line indicates flexible and unresolved RCL residues. The detailed view of the RCL-s2C 
interactions is from the back left with residues 301-302 (s2C), 378-384 (RCL) shown as sticks and 
selected molecules as spheres. The feature enhanced electron density map calculated with PHENIX is 
displayed at 1 ı contour level in red. (B) Feature enhanced maps of RCL and selected s2C residues of 
vaspin E379S contoured at 1 s. (C) corresponding residues of the D305C/V383C variant also 
demonstrating successful formation of the introduced disulfide bond. To more clearly present electron 
density of RCL residues and the disulfide bond, note that the view point for (B) and (C) is slightly rotated 
to the left compared to (A). 
Figure 2. Kinetic analysis for the inhibition of KLK7 by vaspin and mutants. (A) Stoichiometry of 
inhibition was determined by linear regression to extrapolate the inhibitor to enzyme (I0/E0) ratio for 
complete loss of KLK7 activity. (B) Inhibition of KLK7 by vaspin wt and mutants D305C/V383C, 
R302E/E379S and R302A were measured under pseudo-first-order conditions in a discontinuous assay 
using at least six different inhibitor concentrations. The ka was determined as the slope of the linear fit 
after plotting kobs vs. I0. (C) KLK7 inhibition by vaspin E379S was determined by using the progress 
curve method. KLK7 inactivation was monitored for 45 min and kobs was calculated by a non-linear 
regression fit of each curve. Accounting for Km of KLK7 for the peptide substrate, the slope of kobs vs. 
I0 resulted in the ka. The mean values of at least three experiments are reported in Table 2.  
Figure 3. Complex formation analyses of vaspin wild-type and mutants with KLK7 by SDS-
PAGE. (A) Coomassie stained SDS-gels of vaspin wild-type (wt) and mutants D305C/V383C and 
E379S incubated with KLK7 for indicated times and respective control samples without protease. (B) 
Respective Coomassie stained gels for mutants R302A and R302E incubated with KLK7. (C) RP-HPLC 
monitoring of synthetic vaspin RCL comprising peptide vaspin(365-388) incubated with or without 
KLK7 reveals no detectable cleavage (linear gradient of ACN/H2O from 10-50 % in 40 min). (D) 
Coomassie stained gels for mutants R302A/D305C/V383C, R302E/D305C/V383C and R302E/E379S 
incubated with KLK7. Notable and indicated bands are: 1 - serpin-protease complex; 2 - active serpin; 
3 - active, Tag-cleaved serpin; 4 - cleaved serpin; 5 - protease. 
Figure 4. Heparin binding and activation of vaspin. (A) Elution profiles of recombinant wt vaspin 
and KLK7 by heparin-affinity chromatography using a NaCl gradient (black dotted line) monitored at 
220 nm. Vaspin elutes at ~580 mM, KLK7 at 420 mM NaCl. (B) Analysis of concentration dependent 
heparin accelerated complex formation of vaspin and KLK7. Coomassie stained SDS-gel of a fixed 
molar ratio (1:3) of vaspin wild-type (wt) and KLK7 incubated with increasing concentrations of 
unfractionated heparin (0.1–100-fold vaspin) for 1 min and a reference sample without heparin (0x). 
The control (con) is vaspin and heat-inactivated KLK7. (C) Densitometric quantification of complex 
band intensities in relation to the molar ratio of unfractionated heparin (ufh) to vaspin of SDS-gels as in 
(B). A bell-shaped curve is obtained suggesting the bridging mechanism as the major contribution to 
heparin activation of vaspin. (D) Inhibition of KLK7 by vaspin wt with different concentrations of 
unfractionated heparin was measured under pseudo-first-order conditions in a discontinuous assay. 
Presented is the increase in second order rate constant in x-fold over control (without heparin). The ka
values were determined as described in Materials and methods.  
Figure 5. Thermo-stability and heat-induced polymerization of vaspin wild-type and mutants. (A) 
Far-UV CD spectra of vaspin wild-type (wt) and mutants D305C/V383C, E379S, R302A and R302E at 
20 °C are shown (collected in phosphate buffer, pH 7.8, 1.5 μM). (B) CD spectra of vaspin at different 
stages of thermal denaturation from a single sample. (C) Thermal unfolding of vaspin and mutants from 
single samples observed by far-UV CD at 208 nm at a heating rate of 50 °C/h. (D) SDS-PAGE analysis 
of vaspin-KLK7 complex formation or (E) vaspin and ATIII polymerization after incubation at 60 °C 
for indicated times. (F) Heat-induced polymerization for wild-type vaspin and R302A, R302E, E379S, 
R302E/E379S and D305C/V383C variants after incubation at 70 °C for up to 60 min. Mutation of Arg302 
significantly increases polymer formation.  
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Table 1: Details of the crystal structure analysis 
 vaspin D305C/V383C vaspin E379S 
Crystallization and data collection   
Crystallization buffer 6 % (w/v) polyethylene glycol 
6000, 0.1 M citric acid  
pH 3.5–4.5 
2.5 M ammonium sulfate, 
0.1 M sodium citrate  
pH 4.0–4.6 
Crystallization drop 1 μL crystallization buffer  
+1μL of 6 mg/mL protein in 
50 mM Tris pH 7.5, 150 mM 
NaCl 
1μL crystallization buffer 
+1μL of 10.2 mg/mL protein 
in 50 mM Tris pH 7.5, 150 
mM NaCl, 0.52 mM heparin 
tetrasaccharide dp4 
Cryobuffer Crystallization buffer 
+20 % (v/v) ethylene glycol 
Crystallization buffer 
+20 % (v/v) ethylene glycol 
Wavelength (Å) 0.91841 0.91841 
Resolution range (Å)1 19.69  - 2.2 (2.26  - 2.2) 48.37  - 2.2 (2.26  - 2.2) 
Space group C2 C2 
Unit cell parameters a, b, c (Å),  
Į, ȕ, Ȗ (°) 
133.5, 152.3, 61.6,  
90, 97.1, 90 
133.0, 151.4, 61.6,  
90, 98.4, 90 
Total reflections1 342549 (19778) 208807 (15788) 
Unique reflections1 61536 (4375) 60841 (4481) 
Multiplicity1 5.6 (4.5) 3.4 (3.5) 
Completeness (%)1 99.6 (96.3) 99.8 (99.8) 
Mean I/sigma(I) 1 7.9 (0.9) 7.2 (0.9) 
R-merge1 0.145 (1.554) 0.125 (1.413) 
R-pim1 0.067 (0.798) 0.080 (0.885) 
CC1/21 0.996 (0.285) 0.996 (0.206) 
CC*1 0.999 (0.666) 0.999 (0.584) 
Wilson B-factor (Å2) 46.70 45.62 
Monomers/asymmetric unit 2 2 
Refinement   
R-work1 0.1801 (0.2251) 0.1862 (0.2485) 
R-free1 0.2058 (0.2406) 0.2193 (0.2574) 
Protein residues 727  
(chain A: 36-366, 380-414; 
chain B: 34-277, 281-365, 
382-413) 
728  
(chain A: 35-367, 381-414; 
chain B: 35-277, 280-365, 
383-414) 
Number of non-hydrogen atoms   
Total 6237 6224 
Protein  5949 5983 
Ligands 33 53 
Water 255 188 
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Rmsd 
Bonds (Å) 0.009 0.010 
Angles (°) 1.08 1.12 
Ramachandran statistics   
Favored (%) 96.54 95.87 
Allowed (%) 3.46 4.13 
Outliers (%) 0 0 
B-factor (Å2)   
Average 66.445 71.939 
Protein 66.879 72.616 
Chain A 55.418 56.266 
Chain B 78.553 89.148 
Ligands 60.858 59.968 
Water 57.038 53.758 
1values in parenthesis correspond to highest resolution shell 
 
 
 
Table 2. Kinetic parameters for the inhibition of KLK7 by vaspin and mutants 
  
Vaspin variant 
  ka SI 
  mM-1 s-1 I / E (mol / mol) 
 wild-type  12.3 ± 0.3 3.6 ± 0.3 
 D305C/V383C  56.9 ± 9.7 2.0 ± 0.2 
 E379S  403.0 ± 34.4 2.0 ± 0.1 
 R302A  0.3 ± 0.1 2.7 ± 0.6* 
 R302E  0.03 3.2 ± 0.2* 
  R302E/E379S   20.7 ± 4.2 3.2 ± 0.2 
*densitometric estimation; I Inhibitor; E Enzyme; Data presented as averages 
of at least three experiments ± S.D. with exception of ka for R302E. 
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FIGURE 1 
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FIGURE 2 
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FIGURE 3 
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FIGURE 4
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FIGURE 5 
 
 
